Navigation Links
Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
Date:8/12/2008

adverse events were reported in any of these trials.

"We are very pleased with JADA's decision to publish these studies," stated Donna Janson, President and Chief Executive Officer of Novalar. "As the nation's premier dental journal, publication in JADA further demonstrates the quality of our clinical science and allows Novalar the opportunity to begin educating the dental community on the benefits of OraVerse to both patients and clinicians."

About OraVerse

OraVerse (phentolamine mesylate) Injection is the only local anesthetic reversal agent that accelerates the return to normal sensation and function following restorative and periodontal maintenance procedures. OraVerse is indicated for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than six years of age or weighing less than 15 kg (33 lbs). Myocardial infarction and cerebrovascular spasm and occlusion have been reported following parenteral use of phentolamine, usually in association with marked hypotensive episodes producing shock-like states. Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse (phentolamine mesylate), clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease.

About Novalar

Novalar is a specialty pharmaceutical company that partners directly with dental professionals to enrich the patient experience. The company is uniquely positioned to develop targeted oral pharmaceutical products and translate the full value of these novel solutions to clinical practice. For more information, please visit

SOURCE Novalar Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
2. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
3. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
4. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
5. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
6. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
7. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
8. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
9. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
10. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
11. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ORK, Nov. 20 Reportlinker.com anno...le in its catalogue. ,, Medical Adhesives and ...reportlinker.com/p0164242/Medical-Adhesives-and-Se...wire&utm_medium=pr&utm_campaign=prnewswire... is gaining preeminence in medical devices and equ...
(Date:11/20/2009)...H MEETING, Pa., Nov. 20 ...that questions why currently available medications...ing ignored, ECRI Institute, an independent nonpro...dence on Finasteride for Prevention of Prostate C... 2009, New York Times article, " Drugs to Deter ...
(Date:11/19/2009)...eland, Nov. 19 Warner Chilcott plc...ts previously announced secondary offering of 20,0...blic of $22.25 per share. The selling shareholder...ers, DLJ Merchant Banking, J.P. Morgan Partners (a..., L.P., certain other institutional investors and ...
Breaking Medicine Technology:Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Endologix Added to Russell Indexes 50394 1Endologix Added to Russell Indexes 50394 2Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 1Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 2Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 50390 3Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th 50387 1Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th 50387 2Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th 50387 3
...,Alzheimer,s Foundation of America (AFA) today cal...enings, especially in light of research,indicating...recognized,often enough and that early diagnosis c...e interventions. Eric J. Hall, AFA,s chief execut...nior research scientist at the Stanford/VA Aging C...
...of Connective Tissue Oncology, Society held in S...and tolerability of perifosine as a single age...sensitive sarcomas, NEW YORK, Nov. 5 Keryx Bioph...d that preliminary data demonstrating the,tolerabi...) in patients,with refractory, rare sarcomas was p...
Other Medicine Technology:Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 2Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 3Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6
(Date:11/20/2009)...e-USNewswire/ -- The United States Conference of C... changes its health reform bill in order to keep i...ence protection on abortion, protect access to hea...ons for adequate affordability. ,, The bishops ...sappointment" that creates new and unacceptable fe...
(Date:11/20/2009)...wire/ -- The American Dental Association (ADA) tod...A) to establish appropriate classifications for to...ut the safety of whitening products that are often...consultation or examination by a dentist, the Asso...sed tooth whitening or bleaching agents can harm t...
(Date:11/20/2009)...swire/ -- The following is a statement by Charles ...e Association: ,, "The Nevada Health Care Assoc...Leader Harry Reid for his leadership in taking our...g every Nevada seniors, ongoing access to quality ... viability of our state,s vital frontline workforc...
(Date:11/20/2009)...h chronic kidney disease often fail to detect hype...easing a child,s risk for serious heart problems, ...s Center and other institutions. A report of the f...Society of Nephrology. , Researchers compared ...r doctor visits to readings obtained via a special...
(Date:11/20/2009)...upply, study finds , , FRIDAY, Nov. 20 (...prescription drugs is up to one-third cheaper than...dy. , U.S. researchers analyzed 26,852 prescrip...and found that patients who bought a three-month s...ge 29 percent in out-of-pocket costs. After the re...
Breaking Medicine News(10 mins):Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2
... Knowing what someone eats can help doctors predi...tely, according to a new study by scientists in Gr...dietary factors in cardiovascular disease (CVD) ri...the models yield. The study, "Inclusion of Dietar...
...s Meet Strict Quality and Safety Standards , , MI...ion (CCA), the retail clinic industry,s member-bas...irectors that its member clinics are certified and...ds in March of 2007 with input from national medic...
...niversity of Liverpool will launch a new national ...ctions such as HIV and tuberculosis. , The Centre...irman of the Health Protection Agency, is one of 1...ture has received 13.5 million funding from NIHR a...
...mers can ask their pharmacists , , OMAHA, Neb., ...be smart with their money. When it comes to healt...riptions written by physicians to less expensive s...hysicians. This switch can have unwanted effects f...
...., Feb. 10 The Clean Tech Open, the non-,profit t...work, and funding to,make clean tech possible and ...n season today. At its first monthly Breakfast Bri...was keynoted by Kevin,Chen, who directs Green Ener...
...m up to Drive Performance Improvements World Wide ...ion ( www.activplant.com ) announced today that Gl...ork agreement naming Activplant as a recommended b...ed the ease of use that empowers operators, engine...
Other Medicine News:Health News:In Month of the Heart, Scientists Identify Better Way to Predict Heart-Disease Risk 2Health News:Convenient Care Association, Jefferson Medical College Certify Member Convenient Care Clinics 2Health News:Convenient Care Association, Jefferson Medical College Certify Member Convenient Care Clinics 3Health News:Convenient Care Association, Jefferson Medical College Certify Member Convenient Care Clinics 4Health News:Biomedical research center opens in Liverpool 2Health News:Patients Urged to be Aware of Prescription Switching 2Health News:Clean Tech Open Announces $125M+ Raised for Clean Tech Startups; Takes 2009 Competition National 2Health News:Clean Tech Open Announces $125M+ Raised for Clean Tech Startups; Takes 2009 Competition National 3Health News:Activplant Corporation Announces Global Agreement with GlaxoSmithKline 2
Hartman Mosquito Forceps
Halstead Curved Haemostatic Mosquito Forceps - Non-Magnetic
Wills Hospital Utility Forceps
McCullough Utility Forceps
Medicine Products: